688621 Beijing Sun-Novo Pharmaceutical Research
- 52.81
- +0.93+1.79%
Beijing Sun-Novo Pharmaceutical Research News
Sunshine Novo (688621): New orders grew rapidly, Q1 profit side exceeded expectations
The company publishes its 2023 annual report and 2024 quarterly report. For the full year of 2023, the company achieved operating income of 930 million yuan, an increase of 37.76% over the previous year; achieved net profit of 180 million yuan to mother, an increase of 18.08% over the previous year;
Sunshine Novo (688621): New signings maintain high growth, gross margin continues to rise
The incident described that the company released its 2023 annual report and the first quarter report of 2024. It achieved revenue of 932 million yuan for the full year of 2023, an increase of 37.76% over the previous year; achieved net profit of 185 million yuan, an increase of 1
Recent 9.8% Pullback Would Hurt Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621) Insiders
Key Insights Insiders appear to have a vested interest in Beijing Sun-Novo Pharmaceutical Research's growth, as seen by their sizeable ownership The top 8 shareholders own 51% of the company Inst
Commentary on Sunshine Novo (688621) 2023 Report and 2024 First Quarter Report: Independent R&D Achievements Continue to Advance and Wait for Implementation
Incident: Sunshine Novo recently released its report for the first quarter of 2023 and 2024: in 2023, the company achieved revenue of 0.3 billion yuan (+37.8%), net profit of 180 million yuan (+18.1%), deducted from the mother
Sunshine Nuohe: Due to supply-side excesses, the CRO industry will receive a share of the rights and interests of self-developed drugs this year | Direct Performance Report
① “With regard to the relative oversupply side of the domestic industry, the local internal volume has intensified. I believe that as competition deepens and the industry continues to clear up, the competitive landscape will gradually become clear in the future.” ② “If the clinical CRO business can continue to grow steadily and bring more market share and customer resources to the company, then this short-term profit pressure is worth it.”
Sunshine Novo (688621): New business formats are growing rapidly, and new momentum is ready to be launched
Key investment points Growth: Self-development transformation and large-scale clinical business release support. Looking at orders, the company signed new orders of 1,504 billion yuan in 2023, an increase of 36.50% over the previous year, and 2,566 billion yuan in progress, an increase of 2 over the previous year
Sunshine Novo (688621): The profit side exceeded expectations and new orders continued to grow at a high rate in the first quarter
Event Overview On April 26, 2024, Sunshine Nuohe disclosed the 2023 Annual Report and 2024 Quarterly Report: The company achieved operating income of 932 million yuan in 2023, an increase of 37.76% over the previous year; achieved net profit to mother
Sunshine Novo (688621): Steady growth in performance and abundant orders to ensure future growth
Steady growth in performance, with abundant orders to guarantee future growth. In 2023, the company achieved operating income of 932 million yuan, an increase of 37.76%; net profit to mother was 185 million yuan, an increase of 18.08% over the previous year; net profit not attributable to mother
Minsheng Securities released a research report on April 27 stating that it gave Sunshine Novo (688621.SH) a recommended rating. The main reasons for the rating include: 1) two-wheel drive for pharmaceutical research and clinical services, continuing to ex
Minsheng Securities released a research report on April 27 stating that it gave Sunshine Novo (688621.SH) a recommended rating. The main reasons for the rating include: 1) two-wheel drive for pharmaceutical research and clinical services, continuing to expand diversified business fields; 2) rapid expansion of independent R&D pipelines, and strong R&D demand from downstream customers. (Mainichi Keizai Shimbun)
Sunshine Novo (688621): Steady growth in performance, positive implementation of self-research results
Event: The company achieved operating income of 932 million yuan, up 37.8% year on year; net profit to mother was 185 million yuan, up 18.1% year on year. Achieved in the first quarter of '24: operating revenue of $252 million, same
Sunshine Novo (688621): Profit side growth in Q1 surpassed expectations, strong demand for one-stop CRO business
Event: On April 25, 2024, Sunshine Nuohe released its 2023 annual report. The company achieved annual revenue of 932 million yuan, a year-on-year increase of 37.76%; net profit to mother was 185 million yuan, an increase of 18.0 million yuan
Pacific released a research report on April 26 stating that it gave Sunshine Novo (688621.SH) a purchase rating. The main reasons for the rating include: 1) strong clinical business growth throughout the year, with 23Q4 sales expenses dragging down profit
Pacific released a research report on April 26 stating that it gave Sunshine Novo (688621.SH) a purchase rating. The main reasons for the rating include: 1) strong clinical business growth throughout the year, with 23Q4 sales expenses dragging down profit growth; 2) continuous increase in R&D investment and continuous expansion of the talent team; 3) high growth in new signings and ongoing orders, and strong certainty about future performance. (Mainichi Keizai Shimbun)
Express News | Pension appeared as the top ten tradable shareholders of 172 individual stocks in the fourth quarter
Sunshine Novo (688621): Performance is basically in line with expectations, and new orders have maintained rapid growth
Incident Overview (1) Company Announcement 2023 Annual Report: 23 Achieved operating income of 932 million yuan for the full year, an increase of 37.76% over the previous year, and realized net profit of 185 million yuan to mother, an increase of 18.08% over the previous year, and achieved deductions
Sunshine Novo (688621.SH) announced first-quarter results, net profit of 72.7538 million yuan, an increase of 51.77% over the previous year
According to Zhitong Finance App News, Sunshine Nuohe (688621.SH) released its report for the first quarter of 2024. The company's revenue was 252 million yuan, up 8.53% year on year; net profit attributable to shareholders of listed companies was 72.7538 million yuan, up 51.77% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 666.201 million yuan, an increase of 41.68% year on year; basic earnings per share were 0.65 yuan/share.
China Merchants Securities: Demand for outsourcing generic drug development services increases, and the performance of listed companies related to generic CRO maintains a relatively rapid growth rate
From a long-term development perspective, imitation CRO related companies are expected to fully benefit from advanced market demand, business model innovation, and customer base expansion, and achieve continuous growth in performance. First-tier enterprises are expected to increase their market share in industrial upgrading competition.
The Price Is Right For Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621)
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s (SHSE:688621) price-to-earnings (or "P/E") ratio of 35.9x might make it look like a sell right now compared to the market in China, where around h
Express News | Sunshine Novo: Shengpu Pharmaceutical plans to purchase shares of the company for 28 million yuan to 32 million yuan
Express News | Novo Shengtai helped two specifications of tranexamic acid injections obtain marketing approval
Express News | Sunshine Nuohe: Liu Yujing transferred 1.35% of the company's shares to his wife Xu Lili through an agreement
Analysis
Price Target
No Data
